- Home
- GMAB vs RRX Comparison
GMAB vs RRX Comparison
Compare GMAB & RRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- RRX
- Stock Information
- Founded
- GMAB 1999
- RRX 1955
- Country
- GMAB Denmark
- RRX United States
- Employees
- GMAB N/A
- RRX N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- RRX
- Sector
- GMAB Health Care
- RRX
- Exchange
- GMAB Nasdaq
- RRX Nasdaq
- Market Cap
- GMAB 12.1B
- RRX 10.3B
- IPO Year
- GMAB N/A
- RRX 1987
- Fundamental
- Price
- GMAB $22.34
- RRX $134.63
- Analyst Decision
- GMAB Buy
- RRX Strong Buy
- Analyst Count
- GMAB 9
- RRX 9
- Target Price
- GMAB $40.71
- RRX $199.50
- AVG Volume (30 Days)
- GMAB 1.9M
- RRX 664.2K
- Earning Date
- GMAB 02-12-2025
- RRX 02-05-2025
- Dividend Yield
- GMAB N/A
- RRX 1.04%
- EPS Growth
- GMAB 83.82
- RRX N/A
- EPS
- GMAB 16.85
- RRX 2.94
- Revenue
- GMAB $2,988,286,182.00
- RRX $6,033,800,000.00
- Revenue This Year
- GMAB $18.78
- RRX $0.33
- Revenue Next Year
- GMAB $14.98
- RRX $4.25
- P/E Ratio
- GMAB $13.00
- RRX $46.28
- Revenue Growth
- GMAB 30.67
- RRX N/A
- 52 Week Low
- GMAB $18.64
- RRX $130.94
- 52 Week High
- GMAB $31.88
- RRX $185.28
- Technical
- Relative Strength Index (RSI)
- GMAB 65.39
- RRX 29.63
- Support Level
- GMAB $18.74
- RRX $133.75
- Resistance Level
- GMAB $22.55
- RRX $141.14
- Average True Range (ATR)
- GMAB 0.46
- RRX 4.49
- MACD
- GMAB 0.39
- RRX -0.87
- Stochastic Oscillator
- GMAB 94.64
- RRX 12.93
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors and electronic controls, air moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.